PAPILLON finds longer survival with amivantamab in rare EGFR lung cancer
Final randomized PAPILLON results found a six-month median overall-survival advantage with amivantamab plus chemotherapy in EGFR exon 20-mutated non-small cell ...
Tag: Georgetown
POPULAR NEWS
-
Research report: Population-level chloroplast genome insights into population structure, genetic diversity, phylogeny, and divergence time of Prunus mongolica
-
Cross-sectional Pakistani HCV convenience cohort identifies dominant genotype 3a
-
Fuzzy-logic system personalizes aesthetic education pathways for university students
-
Rigid coumarin-linked COF boosts photocatalytic hydrogen production in laboratory tests